FDA considers widening testosterone therapy for men with low libido

The Food and Drug Administration is moving into a regulatory gray zone that could reshape testosterone treatment for millions of men: whether to broaden therapy for men with low libido and low testosterone when no structural or genetic cause is known. The agency is not approving a change yet, but it has signaled that it is considering a wider use case for men with idiopathic hypogonadism, a condition that has long sat between established disease and symptoms often dismissed as aging.

On April 16, the FDA filed a notice in the Federal Register saying its early review of published medical literature on this use “seems promising” and inviting companies that already sell approved testosterone products to contact the agency by April 30, 2026, about a supplemental application. In a press announcement, the agency described the move as an initial step to advance treatment options for men’s health while it weighs whether testosterone replacement therapy should be available for men whose decreased libido is tied to idiopathic hypogonadism.

The stakes go beyond one drug label. The FDA’s own current patient and provider page still says testosterone products are approved only for men who lack or have low testosterone in conjunction with an associated medical condition. A broader indication would mark a real shift in policy and practice, potentially affecting prescribing patterns, insurance coverage and how clinicians decide when a symptom set justifies hormone therapy.

The agency’s caution reflects years of debate over where to draw the line between legitimate hypogonadism and age-related or nonspecific symptoms. On December 10, 2025, the FDA held an expert panel on testosterone replacement therapy for men, a 13-member meeting that included specialists such as Helen L. Mulhall and Landon Trost. Public summaries of that session said panelists urged the agency to ease restrictions on testosterone therapy, expand eligibility beyond men with a clearly identifiable medical cause and even reconsider testosterone’s Schedule III controlled-substance status.

Marty Makary, the FDA commissioner, has said the agency sees an opportunity to help men whose symptoms can significantly affect quality of life, but it also stressed that any expansion would require rigorous scientific evidence and a full review of risks and benefits. That balance matters because testosterone use is already widespread, and the medical literature suggests the potential patient pool is large: one national estimate found about 8.4 million U.S. men age 40 and older may have low total testosterone, while another review put testosterone deficiency at roughly 30% of men ages 40 to 79. If the agency widens the label, the decision could open access for some men who have struggled to get treated while also forcing a harder look at long-term safety, monitoring and the pressure of aggressive marketing on a therapy still defined as much by uncertainty as by demand.